These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 36196170)
1. DRUGGING "UNDRUGGABLE" DISEASE-CAUSING PROTEINS: FOCUS ON SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT) 3. Tweardy DJ Trans Am Clin Climatol Assoc; 2022; 132():61-76. PubMed ID: 36196170 [TBL] [Abstract][Full Text] [Related]
2. TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain. Kasembeli MM; Singhmar P; Ma J; Edralin J; Tang Y; Adams C; Heijnen CJ; Kavelaars A; Tweardy DJ Biochem Pharmacol; 2021 Oct; 192():114688. PubMed ID: 34274354 [TBL] [Abstract][Full Text] [Related]
3. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization. Resetca D; Haftchenary S; Gunning PT; Wilson DJ J Biol Chem; 2014 Nov; 289(47):32538-47. PubMed ID: 25288792 [TBL] [Abstract][Full Text] [Related]
6. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation. Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors. Furtek SL; Matheson CJ; Backos DS; Reigan P Oncotarget; 2016 Nov; 7(47):77998-78008. PubMed ID: 27793003 [TBL] [Abstract][Full Text] [Related]
8. High-throughput thermofluor-based assays for inhibitor screening of STAT SH2 domains. de Araujo ED; Manaswiyoungkul P; Israelian J; Park J; Yuen K; Farhangi S; Berger-Becvar A; Abu-Jazar L; Gunning PT J Pharm Biomed Anal; 2017 Sep; 143():159-167. PubMed ID: 28600954 [TBL] [Abstract][Full Text] [Related]
9. Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins. Takakuma K; Ogo N; Uehara Y; Takahashi S; Miyoshi N; Asai A PLoS One; 2013; 8(8):e71646. PubMed ID: 23977103 [TBL] [Abstract][Full Text] [Related]
10. Validating Signal Transducer and Activator of Transcription (STAT) Protein-Inhibitor Interactions Using Biochemical and Cellular Thermal Shift Assays. Attarha S; Reithmeier A; Busker S; Desroses M; Page BDG ACS Chem Biol; 2020 Jul; 15(7):1842-1851. PubMed ID: 32412740 [TBL] [Abstract][Full Text] [Related]
11. Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. Mandal PK; Gao F; Lu Z; Ren Z; Ramesh R; Birtwistle JS; Kaluarachchi KK; Chen X; Bast RC; Liao WS; McMurray JS J Med Chem; 2011 May; 54(10):3549-63. PubMed ID: 21486047 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease. Zhang L; Wang Y; Dong Y; Chen Z; Eckols TK; Kasembeli MM; Tweardy DJ; Mitch WE Am J Physiol Renal Physiol; 2020 Jul; 319(1):F84-F92. PubMed ID: 32475130 [TBL] [Abstract][Full Text] [Related]
13. SH2 domain binding to phosphopeptide ligands: potential for drug targeting. Kasembeli MM; Xu X; Tweardy DJ Front Biosci (Landmark Ed); 2009 Jan; 14(3):1010-22. PubMed ID: 19273114 [TBL] [Abstract][Full Text] [Related]